Potential treatment for polymorphic light eruption A 2010 phase III, randomized, double blind, placebo controlled, parallel group study was undertaken in Germany, the Netherlands, and Belgium to evaluate the safety and efficacy of subcutaneous implants of melanotan I (16 mg) in patients suffering from polymorphic light eruption (PLE), a condition characterized by a rash following exposure to sunlight
The difference between CJC-1295 Ipamorelin and BPC-157 is that one focuses on growth hormone support, while the other focuses on healing and repair
Call Vitality Medical at (425) 458-1971 to schedule a Copper Peptide Therapy consultation
Aschner P, Kipnes MS, Lunceford JK, et al
y-age glutathione
What previously caused mild fullness might now trigger uncomfortable bloating , excessive burping , or even nausea on top of the side effects your medication already produces